An investigation by senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the drug.» Read More
At least one person was killed in an explosion at an Istanbul metro station, reports CNBC's Sue Herera. Officials don't yet know the source of the explosion.
CNBC's Eamon Javers details the findings of an 8-month probe into Gilead's pricing strategies and "calculated schemes."
Two companies are taking matters into their own hands to help make an alternative to a pricey drug more available to the public.
Rising demand for IVF in China will strain already-crowded state-run hospitals but create opportunities for overseas health centers.
Jim Cramer speaks to the CEO of Allergan, to get a better look at what Allergan shareholders can expect from the world's largest drug merger.
Valeant has drawn scrutiny from Congress, hospitals and patients for sharply increasing their prices, the NYT reports.
A new takeover offer for U.S. biotech firm Baxalta would create one of the world's leading specialists in rare diseases.
Michael Yee, BioTech Analyst, RBC Capital Markets, on why shares of Gilead are up 12 percent so far this year.
Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.
Activist investor Bill Ackman's hedge fund has increased its investment in Valeant, and signaled it may play a greater role in its strategy.
John Burke, CEO, Burke Financial Strategies, explains why he remains bullish on Pfizer shares.
Shares of KaloBios jumped after Martin Skhreli took a 70 percent stake in the name.
Pershing Square Capital Management revealed Monday that it had boosted its stake in Valeant Pharmaceuticals.
Pfizer is buying Allergan for about $160 billion. CNBC's Meg Tirrell reports on the reaction by lobbyists and analysts.
CNBC's Eamon Javers reports on the White House and Democratic Presidential Candidate Hillary Clinton's reaction to the Pfizer-Allergan deal.
CNBC's Meg Tirrell looks at the details of Pfizer's $160 billion acquisition of Allergan.
Barbara Ryan, Clermont Partners, weighs in on terms of the deal which is expected to close in the second half of 2016.
CNBC's Meg Tirrell reports details of the merger which will create the world's largest pharma company to be headquartered in Dublin, Ireland.
CNBC's Meg Tirrell breaks down terms of the deal which would create the world's largest pharma company.
Pfizer's record deal with Allergan will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden.
Get the best of CNBC in your inbox